A small clinical study from Mumbai reports that a cheap combination of two common supplements noticeably changed biological markers in aggressive brain tumors, with no reported side effects in the short term. Researchers gave a resveratrol and copper tablet to half of 20 glioblastoma patients before surgery and compared tumor tissue against untreated controls. The findings are intriguing but strictly preliminary and should not be taken as proof of a cure.
Scientists at the Advanced Center for Treatment, Research and Education in Cancer ran a pilot experiment on 20 patients who were already set to undergo brain surgery for glioblastoma. Ten received the supplement tablet four times daily for about 12 days before surgery, while the other ten served as untreated controls. During operations, surgeons collected tissue to allow direct comparison between treated and untreated tumors.
The study team reported large biological shifts inside treated tumors, including a dramatic fall in biomarkers linked to aggressive behavior. Tumor growth activity showed a roughly 33 percent reduction, and several other measures dropped sharply. Cancer biomarkers fell by 57 percent, immune-checkpoint signals were down 41 percent, and stem cell markers were reduced by 56 percent, all with no side effects recorded during the short intervention.
“These results suggest that a simple, inexpensive and non-toxic nutraceutical tablet potentially has the power to heal glioblastoma,” Mittra said in a statement. The lead researcher and his colleagues saw near-complete removal of particular DNA fragments that drive inflammation in tumors. Those fragments, called cell-free chromatin particles, can worsen tumor behavior when released by dying cells.
“We observed near-complete eradication of cell-free chromatin particles from the cancerous glioblastoma tissues following [the resveratrol and copper] treatment,” Mittra told Fox News Digital. The proposed mechanism is chemical rather than classic drug targeting. Copper enables resveratrol to generate reactive molecules that break down DNA debris thought to fuel inflammation and tumor aggressiveness.
Resveratrol is a polyphenol found in foods like red grapes and berries and has been studied for antioxidant effects. In this pairing with copper, researchers say it acted differently, helping to dissolve the harmful DNA fragments rather than simply serving as an antioxidant. The pairing is cheap and non-toxic in the short window tested, which makes it appealing as an exploratory approach.
The investigators stress that this work challenges the long-standing assumption that eliminating cancer cells is the only path to control. “We have been trying to kill cancer cells for 2,500 years, since the time of the ancient Greeks, without success,” Mittra said. “Maybe it is time to look at cancer treatment differently and work toward healing tumors rather than annihilating them.”
The team is cautious about what the data actually mean for patients because the trial was small and brief. It only measured immediate changes in tumor tissue after roughly 12 days of supplementation and did not track long-term outcomes like survival or recurrence. The physical appearance of the tumors did not change over that short period, so clinical impact remains unknown.
Researchers warned against jumping to unsupervised use of supplements because formulations and dosing matter. “The public should understand that ours is only a first step, and our findings are based on a relatively small number of patients, which needs replication in larger patient cohorts,” Mittra said. “They should not start self-medicating simply because these items are readily available,” he added. “There may be minimal benefit unless the controlled formulation we designed for our study is used.”
Outside experts routinely caution that dietary supplements can interfere with tests and treatments, and safety over time is uncertain for cancer patients. The investigators called for larger, longer, and rigorously controlled trials to see whether the tissue-level changes translate into meaningful clinical benefits. Until then, standard treatments like surgery, radiation and proven systemic therapies remain the established care.
“It should be noted that resveratrol plus copper, including its tablet formulation, is not a substitute for established cancer treatments like surgery, radiotherapy, chemotherapy, hormone therapy and targeted therapy, which have been conclusively proven to provide benefits and result in cures in a substantial proportion of patients,” the statement read. The research group has been following this line of inquiry for over a decade and describes the current trial as an early, hypothesis-generating effort. Larger trials under strict clinical oversight will be needed to test safety, interactions with standard care, and any true survival benefit.
